Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Clinical trial NCT05868629 · RECRUITING
Trial details
- NCT number
- NCT05868629
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-02-06
- Primary completion
- 2028-03-03
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.